Pharmaceutical

Ocugen’s retinal therapy gains FDA orphan drug status

The OCU410ST is intended for the treatment of ABCA4-linked retinopathies.

IN FOCUS: Syngene International

Research company ranked in the Business Expansion and Research and Development c...

Editas grabs orphan drug status for sickle cell disease...

The CRISPR-based gene therapy received the designation from the US FDA for the s...

STAT+: FDA warns of security vulnerability in Illumina’...

DNA sequencing machines have typically been designated for “research use only,” ...

Biden officials propose slate of Medicaid transparency ...

The Biden administration rolled out proposals to set national standards for care...

Listen: Explaining the E.U.’s pharma overhaul, Lilly’s ...

Is a specter haunting Europe? Will Eli Lilly usurp Johnson & Johnson? And what d...

Vast sequencing project begins to unlock human genome’s...

An international research collaboration is revealing how genetics shapes human h...

GoodRx hires former tech exec as CEO, Amazon shutters H...

In the latest edition of STAT's Health Tech newsletter: GoodRx hires former tech...

Virtual Event: Breakout Stars in Science

STAT sits down for a conversation with past all-star Wunderkinds to see where th...

STAT+: Pharmalittle: Lilly’s Mounjaro helped people los...

Eli Lilly’s drug Mounjaro for type 2 diabetes helped people who are also overwei...

STAT+: Eli Lilly’s Mounjaro succeeds in second weight l...

The drug giant Eli Lilly said its diabetes drug Mounjaro helped patients with th...

STAT+: Six months after launch, Bert Vogelstein’s lates...

Six months after launch, a startup founded by three leaders in the blood testing...

A research team airs the messy truth about AI in medici...

In public, hospitals rave about artificial intelligence. But on the front lines,...

STAT+: Pharma executives shower Bill Cassidy with campa...

Sen. Bill Cassidy’s new perch as the top Republican on the Senate health committ...

STAT+: Health insurance CEOs set another record for pay...

The CEOs of seven major health insurers together made more than $335 million in ...

Opinion: A judge’s infuriating ruling on vaccination pu...

Already, rumors are flying that vaccine opponents in other states will try to fo...